Clinical Trial Update: Immunogenicity, Reactogenicity of Shingrix in SLE [Phase 3]

View source ↗

Summary

A Phase 3 trial update evaluating the immunogenicity and reactogenicity of Shingrix in patients with systemic lupus erythematosus (SLE).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus
• Zoster

Drugs mentioned

• Shingrix (recombinant zoster vaccine, adjuvanted)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Zoster, Systemic Lupus Erythematosus | Phase 3 | Status: UNKNOWN